A flat review · two peptides, one record
BPC-157 TB-500 is the two-peptide Wolverine blend, reviewed finding by finding from the published record.
Two peptides, two mechanisms, one contested combination claim. We read each constituent against its own studies, mark the blend-level gaps in plain sight, and put the regulatory-access status first.
Two peptides on one record
BPC-157 TB-500 is not a single molecule. It is a research-community pairing of two distinct synthetic peptides, marketed and discussed under the name "Wolverine" as a tissue-repair stack. BPC-157 is a 15-amino-acid pentadecapeptide (sequence GEPPPGKPADDAGLV, ~1419.5 Da) derived from a protein found in human gastric juice. TB-500 is a 7-amino-acid acetylated heptapeptide, Ac-LKKTETQ (~889 Da), matching the actin-binding region of Thymosin Beta-4 [3][5].
Review this site the way you would read a record sleeve. Each constituent is a side. BPC-157 carries the cytoprotective, pro-angiogenic signal; TB-500 carries the cytoskeletal, cell-migration signal. The page states each claim loud and sets the species, dose, and route quiet beneath it — and where the claim is about the blend rather than a single peptide, it carries no color at all, because the controlled combination study that would justify it does not exist [6].
That absence is the through-line. The Wolverine blend has no single molecular weight, no CAS number, and no validated combination dose, half-life, or human safety profile. What it has is two well-characterized constituents and a synergy claim that is an extrapolation from their separate mechanisms — a claim this review treats as unproven until a study tests the two peptides together [6]. Read BPC-157 and TB-500 mechanisms in review, then why the literature pairs the two peptides.
The Wolverine stack: a reviewer's overview of BPC-157 and TB-500
The BPC-157 TB-500 stack pairs a local repair signal with a migration signal. BPC-157 up-regulates VEGFR2 and drives downstream Akt-eNOS angiogenic signaling, and it accelerated healing of a fully transected rat Achilles tendon across biomechanical, functional, and microscopic measures at 10 μg/kg or 10 ng/kg intraperitoneally [1][2]. TB-500's LKKTETQ motif binds monomeric G-actin 1:1 and sequesters it, regulating the cytoskeletal dynamics that drive cell migration and re-epithelialization [3].
The pairing is rational on paper because the two mechanisms are complementary and largely non-overlapping. It is not validated in practice because no peer-reviewed study has dosed the two peptides together and measured a combined endpoint [6]. A reviewer's overview, then, is a tale of two strong single-compound literatures and one untested join.
A second caveat sits underneath the stack. Most of the efficacy data attributed to "TB-500" were generated with full-length Thymosin Beta-4 (~4963 Da), not the Ac-LKKTETQ heptapeptide that is actually sold [4][5]. The blend inherits that gap: one of its two sides leans on data for a larger parent molecule. See the BPC-157 vs. TB-500 differences for how the two constituents diverge.
What is the Wolverine peptide blend?
The Wolverine peptide blend is a research-community name for a two-peptide pairing of BPC-157 and TB-500, marketed and discussed as a tissue-repair stack. It is not a single chemical entity. It has no single molecular weight or CAS number, and it is not an approved product anywhere [6].
The "wolverine peptide" search term is partly conflated with the comic-book character, so treat it as a branded blend label rather than a clean compound signal. On this site the name is shorthand for the two constituents and the contested claim that joining them produces more than either alone.
What is the Wolverine peptide blend?
Wolverine is a research-community name for a two-peptide pairing of BPC-157 and TB-500, marketed as a tissue-repair stack. It is not a single chemical entity, has no single molecular weight or CAS number, and is not an approved product anywhere. The pairing is discussed in athlete forums and research-peptide marketing far more than it appears in the controlled literature [6].
What is BPC-157 and TB-500?
BPC-157 is a synthetic 15-amino-acid pentadecapeptide (GEPPPGKPADDAGLV) derived from a human gastric-juice protein, and TB-500 is a synthetic N-acetylated heptapeptide (Ac-LKKTETQ) matching residues 17-23 of Thymosin Beta-4 [3][5]. The Wolverine blend pairs the two as a tissue-repair stack; it is not a single chemical entity and not an approved product.
What is the BPC-157 and TB-500 blend used for in research?
In preclinical work the two constituents occupy complementary nodes of a tissue-repair network: BPC-157 for cytoprotection, angiogenesis, and tendon/ligament repair in rodent models, and TB-500 / Thymosin Beta-4 for cell migration, re-epithelialization, and wound healing in animal and biochemical models [1][2][3][4]. The assembled blend itself has not been tested in a controlled study [6].
Where the recovery narrative is overstated
A reviewer's job includes flagging where the popular story outruns the evidence, and with this blend it does so in three predictable places. First, a large share of the BPC-157 foundational literature comes from a single research group, which is exactly the independent-replication question newer reviews now raise explicitly [8]. Second, the preclinical record is not uniformly positive: in dystrophin-deficient mdx mice, chronic Thymosin Beta-4 increased regenerating fibers but did not improve strength or cardiac function, and a rat embolic-stroke study found Thymosin Beta-4 dosing non-monotonic, with 18 mg/kg giving no benefit [4]. Third, the common online claims — rapid healing of any injury, reliable performance enhancement — rest on animal, single-compound data, not on the combined blend [6].
None of that erases the genuine findings. The transected-Achilles result is real [1]; the VEGFR2 angiogenesis mechanism is real [2]; the 1:1 actin-sequestration structure is real [3]. The point is calibration: strong single-compound signals, a plausible pairing rationale, and an evidence gap exactly where the marketing is loudest.
How this review reads the record
Every quantitative claim on this site is tied to a numbered study you can check on the full reference list. Doses are reported as they were administered — "studied at X μg/kg in [species]" — never as a human instruction, because neither constituent is approved for human use and the blend has no validated dose [6]. The dosage ranges reported in preclinical studies are presented as animal-model figures, and the BPC-157 TB-500 combination research is read as a mechanism rationale awaiting a study, not a proven protocol.
The regulatory status is not a footnote here; it is a liner note read up front. In 2023 the FDA placed both BPC-157 and the Thymosin Beta-4 LKKTETQ fragment in a category of bulk drug substances that may present significant safety risks, restricting their use in 503A pharmacy compounding [9]. Both are also prohibited in sport under the WADA prohibition status set out on the legal-status page [5]. The Wolverine legal status and FDA 503A category page sets that record out in full.
What you will not find here is a price, a vendor, or a protocol. This is a listening room for the literature, not a store. The findings get to be colorful; the frame says nothing it cannot prove.